The STEP-1 body-composition substudy (n=140 DXA cohort) of semaglutide (Wegovy at 2.4 mg weekly) reported fat-free mass loss of approximately 6.9 kg over 68 weeks, accounting for approximately 45% of total weight loss based on the body-composition substudys own arithmetic and the Conte 2024 systematic review [6, 7]
Saunders KO, Lee E, Parks R, Martinez DR, Li D, Chen H, et al
What temperature controls are in place during shipping
The needle you choose directly impacts the quality and consistency of your research data
Digestive discomfort A rare but possible effect in sensitive individuals
This sharp departure in policy to allow sharing of Medicaid enrollee data with ICE for immigration enforcement raises several key issues: Data limitations may make it difficult for CMS to comply with a current court order to share data only for individuals who are not lawfully present for the 22 plaintiff states challenging the data sharing